Engineered T cells: the promise and challenges of cancer immunotherapy.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic review methodology or primary data.
PubMed 27550819 · doi:10.1038/nrc.2016.97
What was done
This is a narrative review summarizing advances in cancer immunotherapy using adoptive transfer of genetically engineered T cells, focusing on chimeric antigen receptors (CARs), engineered T-cell receptors (TCRs), and next-generation designs.
What was found
The abstract reports no numerical findings, statistics, or effect sizes. It qualitatively describes clinical trials using CAR- and TCR-engineered T cells as having produced notable responses in patients with relapsed or refractory hematological malignancies.
Why it matters
It outlines the principles and developmental pipeline of engineered T cells as living therapeutics capable of overcoming tumor immunosuppression in refractory hematologic cancers.
Limits
The abstract provides no primary human or animal data, quantitative outcomes, or systematic literature search methodology. Efficacy in solid tumors and adverse effects are not detailed in the abstract.
Cited by
- supports CAR-T cell therapy involves genetically engineering T cells with a synthetic chimeric antigen receptor designed in the lab to target and destroy cancer cells upon reinfusion into a patient.